Cardio Diagnostics Holdings, a genetic testing, precision cardiovascular medicine company, announced the launch of PrecisionCHD, a combined genetic and epigenetic blood test that can detect coronary heart disease at an early stage.  

Precision CHD is the company’s second clinical test after Epi+GenCHD and is built using the AI-driven Integrated Epigenetic-genetic Engine. Both tests cover all aspects of coronary heart disease, ranging from evaluating the likelihood of developing it for preventive purposes, to early detection.

Additionally, Precision CHD includes an Actional Clinical Intelligence platform, which is exclusively available for healthcare providers. This platform assesses a patient’s distinctive biomarker profile with controllable risk factors including diabetes, high blood pressure, high cholesterol levels, and smoking, which are recognized as significant contributors to coronary heart disease. PrecisionCHD has a sensitivity of over 75% for detecting coronary heart disease in both females and males and can be conducted in healthcare facilities or remotely using a combination of at-home sampling and telehealth options. 

Cardio Diagnostics Holdings is a company that specializes in precision cardiovascular medicine and uses AI to enhance accessibility, personalization, and accuracy in preventing and detecting cardiovascular disease. The company was founded with the aim of promoting and selling clinical tests that use a distinctive Integrated Genetic-epigenetic Engine powered by AI.